Share this post:

Jim O’Neill covers the launch of the new AMR Benchmark and the necessary data that will be used to make progress on the crucial public-health issue of AMR. The former Chairman of the Review on Antimicrobial Resistance hopes that the many companies that have not been carrying their weight will finally feel compelled to act.

“Let us hope the pharmaceutical benchmark gets the attention it deserves.”

Read full article